MWNA
TCRR

Marshall Wace North America’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Marshall Wace North America’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$4.63M Buy
+543,582
New +$7.68M 0.02% 530
2021
Q2 		– Sell
-503,860
Closed -$11.1M – 1896
2021
Q1 		$11.1M Sell
503,860
-479,007
-49% -$13.1M 0.05% 372
2020
Q4 		$30.4M Buy
982,867
+450,366
+85% +$11.4M 0.14% 181
2020
Q3 		$10.8M Buy
+532,501
New +$9.35M 0.07% 270

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Marshall Wace North America's TCRR Position: Q3 2021 in Review

Marshall Wace North America opened a new position in TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2021: 543,582 shares worth $4.63M. The stake represents 0.02% of the portfolio and ranks #530 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in TCRR as recently as Q1 2021.

Marshall Wace North America first reported a position in TCRR in Q3 2020 and has held it in 4 quarters since. The position peaked at $30.4M in Q4 2020. 117 funds tracked by Wall St. Rank hold TCRR as of Q3 2021.

  • Marshall Wace North America held 543,582 shares of TCR2 Therapeutics Inc. Common Stock worth $4.63M as of Q3 2021.
  • TCR2 Therapeutics Inc. Common Stock was a new Marshall Wace North America position in Q3 2021.
  • TCR2 Therapeutics Inc. Common Stock made up 0.02% of Marshall Wace North America's portfolio in Q3 2021, its #530 holding.
  • Marshall Wace North America first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2020 and has held it in 4 quarters since.
  • Marshall Wace North America's TCR2 Therapeutics Inc. Common Stock position peaked at $30.4M in Q4 2020.
  • 117 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.